AstraZeneca, RDIF show interest in Telangana's global tender for Covid shots

The last date to submit the quotation is June 4.

astra
Photo: Bloomberg
Press Trust of India Hyderabad
2 min read Last Updated : May 27 2021 | 6:50 PM IST

AstraZeneca and Russia's Sputnik V are the only two vaccine manufacturers which have participated in a pre-bid meeting held by Telangana government for procuring 10 million doses of COVID-19 vaccine, though the conference witnessed participation of a few trade representatives, sources said on Thursday.

The pre-bid meeting was held on May 26.

The last date to submit the quotation is June 4.

Telangana recently issued aglobale-tendernotice for procuring ten million doses of COVID-19 vaccine from manufacturers or their agents in case of imported jabs.

"Representatives of AstraZeneca and Sputnik V participated, though some trade representatives also took part in the pre-bid meeting," sources close to the development told PTI.

The bidders can quote their offers to supply the vaccine in part also, provided that monthly supply shall not be less than 1.5 million and the total supply of 10 million doses shall be completed within six months from the issuance of Letter of Intent (LoI), according to the tender document.

Any vaccine supplier should comply with the standards set by the Drug Controller General of India for the jabs, sources add.

AstraZeneca sells two COVID-19 vaccines.

It tied up with Serum Institute and rolled out Covishield in India while it sells the jab under brand name Vaxzevria in Europe and other countries.

Russian Direct Investment Fund inked a pact with Dr Reddy's Laboratories for the first 125 million people doses (250 million vials) of Sputnik V in India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: May 27 2021 | 6:45 PM IST

Next Story